与阿司匹林或克洛皮多格雷尔相比,阿司匹林加克洛皮多格雷尔在急性缺血性中风中降低了感染风险
Zhangfeng Yu1, Zheng Huang2, Juan Wu3
1Department of Emergency and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu Province, China; Gusu School of Nanjing Medical University, Suzhou, Jiangsu Province, China.
Clinical therapeutics
|April 3, 2025
概括
与阿司匹林和克洛皮多格雷尔的双重抗血小板治疗相比,与单一药物治疗相比,显著降低了中风后感染的风险,特别是肺炎.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板在免疫反应中发挥作用.
- 脑卒中后的免疫抑制会增加感染风险.
- 血小板抑制可以减轻中风后的感染.
研究的目的:
- 评估抗血小板剂对中风后感染风险的影响.
- 评估血小板抑制对中风后感染的贡献.
- 为了比较单独使用阿司匹林,单独使用克洛皮多格雷尔和双重治疗的感染风险.
主要方法:
- 对975名急性缺血性中风患者进行前性队列研究.
- 对阿司匹林,克洛皮多格雷尔和双重治疗的7天内感染风险的比较.
- 多变量考克斯比例危险回归分析.
主要成果:
- 双重抗血小板治疗 (阿司匹林+克洛皮多格雷尔) 与单独使用阿司匹林 (HR 0.41) 和单独使用克洛皮多格雷尔 (HR 0.46) 相比,减少了感染风险.
- 阿司匹林和克洛皮多格雷尔单一治疗之间感染风险没有显著差异.
- 与单独使用阿司匹林相比,双重治疗特别降低了肺炎风险.
结论:
- 使用阿司匹林和克洛皮多格勒的双重抗血小板治疗与较低的中风后感染率有关.
- 这表明,阿司匹林和克洛皮多格雷尔联合剂对中风后的感染具有净保护作用.
- 研究结果支持使用双抗血小板治疗来减少传染性并发症.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
420
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
420
Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Healthcare Associated Infections II: Preventive Measures
2.3K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.3K
Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
124
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124


